Elevation Oncology Inc (ELEV)
Company Info
Highlights
$20.73M
-$0.78
-$9.00K
-$33.65M
$0.22 - $4.33
$1.06
17.83%
4.01
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Elevation Oncology Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Elevation Oncology Inc (ELEV) returned -39.03% year-to-date (YTD) and -90.23% over the past 12 months.
ELEV
-39.03%
31.92%
-47.22%
-90.23%
N/A
N/A
^GSPC (Benchmark)
-3.77%
3.72%
-5.60%
8.55%
14.11%
10.45%
Monthly Returns
The table below presents the monthly returns of ELEV, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 23.21% | -24.42% | -50.54% | 43.42% | -7.70% | -39.03% | |||||||
| 2024 | 417.69% | 58.63% | 16.33% | -30.80% | 13.24% | -32.84% | -2.59% | -70.42% | -22.89% | -4.27% | 10.74% | -11.54% | 4.77% |
| 2023 | 5.26% | 10.25% | 72.34% | 38.42% | 60.46% | -63.98% | -21.05% | -36.33% | -13.27% | -27.56% | 10.83% | 0.94% | -43.47% |
| 2022 | -27.41% | -22.65% | -25.44% | 21.83% | -26.38% | -38.05% | -10.00% | -8.73% | -1.74% | -4.42% | -16.30% | 5.09% | -84.22% |
| 2021 | 18.62% | -39.57% | 42.68% | -33.42% | 6.16% | -20.72% | -8.19% | -47.38% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ELEV is 8, meaning it’s performing worse than 92% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Elevation Oncology Inc (ELEV) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Elevation Oncology Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Elevation Oncology Inc was 98.55%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Elevation Oncology Inc drawdown is 97.87%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.55% | Jul 13, 2021 | 940 | Apr 8, 2025 | — | — | — |
| -5.54% | Jul 6, 2021 | 2 | Jul 7, 2021 | 3 | Jul 12, 2021 | 5 |
| -2.73% | Jul 1, 2021 | 1 | Jul 1, 2021 | 1 | Jul 2, 2021 | 2 |
Volatility
Volatility Chart
The current Elevation Oncology Inc volatility is 25.67%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Elevation Oncology Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Elevation Oncology Inc, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 19.4% positive surprise.
Valuation
The Valuation section provides an overview of how Elevation Oncology Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ELEV relative to other companies in the Biotechnology industry. Currently, ELEV has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ELEV in comparison with other companies in the Biotechnology industry. Currently, ELEV has a P/B value of 0.3. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |